June 2019
-
Media ReleaseSandoz enters agreement with Kit Check to track, automate restocking of products in U.S. hospitalsSandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently Collaboration will optimize…
-
Media ReleaseNew Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacyData show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis1…
May 2019
-
Media ReleaseSandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growthTwo-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments Realignment of organization involves a planned…
-
Media ReleaseSandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation systemSandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's…
April 2019
-
Media ReleaseSandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumorsCollaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement, EirGenix…
-
Media ReleaseNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgradedTransformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations2 Continuing operations net sales up 7% (cc1, +2% USD) driven by…
-
Media ReleaseSandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countriesAgreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine for…
-
Media ReleaseSandoz resubmits biosimilar pegfilgrastim application to US FDASandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one of the…
March 2019
-
Media ReleaseNovartis announces change in Sandoz leadershipRichard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced today that…
-
Media ReleaseThree winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSWSandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and…